SCHEMBL15465475

SCHEMBL15465475

COc1ccc(CN(c2ccncn2)S(=O)(=O)c2cc(F)c(F)cc2Cl)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.39
CYP3A4 P08684 7/20 0.39
CYP2D6 P10635 7/20 0.39
CYP2C19 P33261 7/20 0.39
TSHR P16473 6/20 0.39
ALDH1A1 P00352 5/20 0.39
CYP2C9 P11712 4/20 0.39
HSD17B10 Q99714 3/20 0.39
HIF1A Q16665 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 3/20 0.36
HDAC8 Q9BY41 1/20 0.35
GAA P10253 2/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
KCNH2 Q12809 1/20 0.35
CLK4 Q9HAZ1 3/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29481979 0.92 POLB (0.41) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL14934588 0.92 POLB (0.41) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL323257 0.91 POLB (0.39) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20485937 0.91 KDM4E (0.42) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL25090187 0.90 POLB (0.38) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL23140884 0.89 POLB (0.38) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20095675 0.88 POLB (0.37) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20238577 0.88 POLB (0.37) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL29669041 0.88 POLB (0.37) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL29481973 0.88 POLB (0.40) CYP1A2CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144300-B1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES DAIICHI SANKYO CO LTD (JP) 2017-12-20 EP disclosed
US-9845313-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-12-19 US disclosed
EP-3144300-A1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES Daiichi Sankyo Company, Limited (JP) 2017-03-22 EP disclosed
US-20170001984-A1 CYCLOALKANE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-01-05 US disclosed
US-9493448-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-15 US disclosed
EP-2813491-B1 CYCLOALKANE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-02 EP disclosed
EP-2813491-A1 CYCLOALKANE DERIVATIVE Daiichi Sankyo Co., Ltd. (JP) 2014-12-17 EP disclosed
US-8889741-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-18 US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001984-A1 CYCLOALKANE DERIVATIVES TRPV1, TRPA1, SCNN1A CYP1A2 2162/4885CYP3A4 3744/4885CYP2D6 1945/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A CYP1A2 2162/4885CYP3A4 3744/4885CYP2D6 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.